Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation
- PMID: 23897007
- PMCID: PMC9445409
- DOI: 10.1245/s10434-013-3140-1
Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation
Abstract
Background: The objective of this work was to evaluate the feasibility of histopathological analysis of tissue extracted on multitined electrodes and assess whether tissue characteristics can be used as biomarkers of oncologic outcomes after lung tumor radiofrequency (RF) ablation.
Methods: Treatment-related data regarding RF ablation of lung malignancies at our institution was collected using a Health Insurance Portability and Accountability Act-compliant ablation database. Institutional review board waiver was obtained for this study. Immunohistochemical analysis of tissue extracted from the electrodes after lung tumor RF ablation was performed for proliferation (Ki-67) and apoptosis (caspase-3). Patient, tumor demographics, and ablation parameters were recorded. Local tumor progression-free survival (LPFS), disease-specific survival (DSS), and overall survival (OS) were assessed using Kaplan-Meier methodology. Multivariate analysis determined factors affecting these oncological outcomes.
Results: A total of 47 lung tumors in 42 patients were ablated; 30 specimens were classified as coagulation necrosis (CN) and 17 as Ki-67-positive (+) tumor cells (viable). Tumor sizes were similar in the CN and Ki-67+ groups (P = 0.32). Median LPFS was 10 versus 16 months for Ki-67+ and CN groups, and 1-year LPFS was 34 and 75 %, respectively (P = 0.003). Median OS was 20 and 46 months (P = 0.12), and median DSS was 20 and 68 months (P = 0.01) for the Ki-67 + and CN groups, respectively. Identification of Ki-67+ tumor cells more than tripled the risk of death from cancer [hazard ratio (HR) = 3.65; 95 % confidence interval (95 % CI), 1.34-9.95; P = 0.01] and tripled the risk of local tumor progression (LTP) (HR = 3.01; 95 % CI, 1.39-6.49; P = 0.005).
Conclusions: Ki-67+ tumor cells on the electrode after pulmonary tumor RF ablation is an independent predictor of LTP, shorter LPFS, and DSS.
Figures
Similar articles
-
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies.Ann Surg Oncol. 2012 Dec;19(13):4262-9. doi: 10.1245/s10434-012-2461-9. Epub 2012 Jul 3. Ann Surg Oncol. 2012. PMID: 22752375 Free PMC article.
-
Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results.Radiology. 2008 Oct;249(1):364-74. doi: 10.1148/radiol.2491071752. Radiology. 2008. PMID: 18796687
-
Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.Ann Surg Oncol. 2013 Mar;20(3):1005-12. doi: 10.1245/s10434-012-2727-2. Epub 2012 Nov 1. Ann Surg Oncol. 2013. PMID: 23115005
-
A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis.Cardiovasc Intervent Radiol. 2022 Aug;45(8):1102-1113. doi: 10.1007/s00270-022-03116-z. Epub 2022 Mar 30. Cardiovasc Intervent Radiol. 2022. PMID: 35355094
-
Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.Front Immunol. 2023 Nov 1;14:1268331. doi: 10.3389/fimmu.2023.1268331. eCollection 2023. Front Immunol. 2023. PMID: 38022658 Free PMC article. Review.
Cited by
-
Percutaneous ablation of liver metastases from colorectal cancer: a comparison between the outcomes of ultrasound guidance and CT guidance using propensity score matching.Ultrasonography. 2023 Jan;42(1):54-64. doi: 10.14366/usg.21212. Epub 2022 Aug 10. Ultrasonography. 2023. PMID: 36464955 Free PMC article.
-
Microwave Ablation in the Management of Colorectal Cancer Pulmonary Metastases.Cardiovasc Intervent Radiol. 2018 Oct;41(10):1530-1544. doi: 10.1007/s00270-018-2000-6. Epub 2018 May 29. Cardiovasc Intervent Radiol. 2018. PMID: 29845348 Free PMC article.
-
Feasibility of a Modified Biopsy Needle for Irreversible Electroporation Ablation and Periprocedural Tissue Sampling.Technol Cancer Res Treat. 2016 Dec;15(6):749-758. doi: 10.1177/1533034615608739. Epub 2015 Oct 6. Technol Cancer Res Treat. 2016. PMID: 26443800 Free PMC article.
-
High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma.Oncotarget. 2017 Jul 21;8(33):55298-55307. doi: 10.18632/oncotarget.19426. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903420 Free PMC article.
-
Ki-67 expression in pulmonary tumors.Transl Lung Cancer Res. 2016 Oct;5(5):547-551. doi: 10.21037/tlcr.2016.10.13. Transl Lung Cancer Res. 2016. PMID: 27827465 Free PMC article. No abstract available.
References
-
- Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8. - PubMed
-
- Pua BB, Solomon SB. Radiofrequency ablation of primary and metastatic lung cancers. Semin Ultrasound CT MR. 2009;30:113–24. - PubMed
-
- Crocetti L, Lencioni R. Radiofrequency ablation of pulmonary tumors. Eur J Radiol. 2010;75:23–7. - PubMed
-
- Thanos L, Mylona S, Ptohis N, Tsiouris S, Sotiropoulou E, Pomoni A, et al. Percutaneous radiofrequency thermal ablation in the management of lung tumors: presentation of clinical experience on a series of 35 patients. Diagn Interv Radiol. 2009;15: 290–6. - PubMed
-
- Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243:268–75. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials